NextCell Pharma presents at the Advanced Therapies Europe conference

September 5, 2023

NextCell Pharma participates in Advanced Therapies Europe, a European conference in Portugal on advanced cell therapies. NextCell's CSO Dr. Lindsay Davies will talk about NextCell's platform technology and the internationally recognized research generated during the development of drug product ProTrans for type 1 diabetes.

NextCell Pharma was invited to present at the Advanced Therapies Europe conference, which will take place 5 – 7 September 2023 in Portugal. NextCell participates through CEO Mathias Svahn and CSO Lindsay Davies who will talk about NextCell's research with the cell therapy drug ProTrans for the treatment of type 1 diabetes.

– For NextCell, the conference is a very good arena to present data from our clinical trials and establish contacts with potential partners and licensees for our drug candidate ProTrans, says NextCells Pharma's CEO Mathias Svahn.

Link to Advanced Therapies Europe https://advancedtherapieseurope.phacilitate.com

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma

For more information about Cellaviva, please contact
Sofie Falk Jansson, Head of Cellaviva
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser, info@fnca.se.

About NextCell Pharma AB
NextCell is a cell therapy company in clinical phase II. The company has developed a proprietary and patented platform technology to produce mesenchymal stromal cells adapted for allogeneic treatment of various autoimmune and immunological diseases. The drug candidate ProTrans is now being tested for the treatment of type-1 diabetes as well as respiratory complications caused by Sars-CoV-2 infection. The focus is to take ProTrans to market approval for type-1 diabetes via a phase III study. ProTrans is evaluated in two clinical COVID-19 studies, in Sweden and Canada. NextCell is working on completing its own GMP facility for the manufacture of ProTrans. The GMP facility is expected to be ready for manufacturing smaller quantities of ProTrans in 2023. NextCell also owns 8.5% of FamicordTX, a start-up company in CAR-T and oncology, and 100% of Cellaviva, Scandinavia's largest stem cell bank for family savings of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

Download attachment Read full press release on Cision (external link)

2024-11-18

QVance Announces Partnership

NextCell Pharma AB* comments on its subsidiary QVance’s partnership with bioMérieux Sweden AB, which aims to strengthen quality control analytics for cell and gene therapy products in the Nordic region. The collaboration will enhance QVance’s capacity to provide microbiological testing for advanced therapies.

Read more Read more

2024-11-08

QVance AB Publishes Article on Particulates in Cell and Gene Therapy Products in Collaboration with ISCT

NextCell Pharma AB* announces that its subsidiary, QVance AB, has published an article in collaboration with the International Society of Cell and Gene Therapy (ISCT). The article, authored by Dr. Lindsay Davies, CSO at NextCell and co-founder of QVance, was published in Cytotherapy and is based on a global survey examining knowledge on particulates in cell and gene therapy (CGT) products.

Read more Read more

2024-11-04

NextCell Pharma AB participates in BIO-Europe 2024 and welcomes a visit from Minister Ebba Busch

NextCell Pharma AB* proudly announces its participation in BIO-Europe 2024, one of Europe’s most significant partnering conferences in biotechnology and pharmaceutical development. The event will be held at Stockholmsmässan from November 4-6, and is expected to gather over 5,000 leading professionals from around the world.

Read more Read more

2024-10-24

NextCell publishes its Year-End Report 2023/2024

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2023 – August 31, 2024. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Read more Read more

2024-10-08

NextCell Pharma invited to present in Tokyo

NextCell Pharma AB's* CEO, Mathias Svahn, has been invited by Business Sweden to the Swedish Embassy in Tokyo, to present the company’s ongoing development at an event on October 8, 2024. The event will focus on innovations in AI and healthcare, where Swedish and Japanese stakeholders will gather to discuss how future healthcare solutions can be developed through collaboration.

Read more Read more

2024-10-04

ProTrans highlighted as a promising treatment for type 1 diabetes in Dagens Medicin

NextCell Pharma AB* is proud that their drug candidate ProTrans has been highlighted in Dagens Medicin’s latest edition featuring ongoing research advances in the treatment of type 1 diabetes. ProTrans consists of mesenchymal stromal cells from the umbilical cord and has been investigated in a number of clinical studies at Uppsala University Hospital, where its potential to slow down the progression of the disease has been demonstrated.

Read more Read more

2024-10-01

The first children have been treated in the younger age group of the ProTrans-Young study

NextCell Pharma AB ("NextCell" or the "Company", Nasdaq First North Growth Market: NXTCL), announces that the first four children in the 7–11 year age group have been treated in the latest phase of the ProTrans-Young study. An additional four children have been screened and are expected to begin their treatment shortly. These advancements mark an important milestone in the progress of the study, which is proceeding faster than anticipated.

Read more Read more

2024-09-05

Broader health benefits of ProTrans in treatment of type 1 diabetes

NextCell Pharma AB ("NextCell" or the "Company", Nasdaq First North Growth Market: NXTCL), has presented new long-term clinical data at the International Society for Cell and Gene Therapy (ISCT) 2024 Regional Meeting, held in Gothenburg, Sweden. The results show the long-term safety of the treatment, the effect of preserving the patient's own insulin production and more health benefits in patients with type 1 diabetes (T1D), such as lower BMI and blood pressure.

Read more Read more